Back to discover

Protein / target

Survival motor neuron protein

Encoded bySMN1Q16637Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
1
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

Identical protein binding

Strongest disease association

Spinal Muscular Atrophies of Childhood

Via encoding gene SMN1 · Genetic evidence · score 0.93

Therapeutic position

Established drug target

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs.

View complete UniProt function annotation

The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:18984161, PubMed:9845364). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:18984161). To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A forming an intermediate (PubMed:18984161). Within the SMN complex, SMN1 acts as a structural backbone and together with GEMIN2 it gathers the Sm complex subunits (PubMed:17178713, PubMed:21816274, PubMed:22101937). Binding of snRNA inside 5Sm ultimately triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP (PubMed:31799625). Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development (PubMed:23063131). Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination (PubMed:26700805). May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs)

Subcellular location

Nucleus, gemNucleus, Cajal bodyCytoplasmCytoplasmic granulePerikaryonCell projection, neuron projectionCell projection, axonCytoplasm, myofibril, sarcomere, Z line
Domains and Gene Ontology detail (21)

Domains & features

Tudor

Gene Ontology

  • Caxon
  • CCajal body
  • Ccytoplasm
  • Ccytoplasmic ribonucleoprotein granule
  • Ccytosol
  • CGemini of Cajal bodies
  • Cneuron projection
  • Cnuclear body
  • Cnucleoplasm
  • Cnucleus
  • Cperikaryon
  • CSMN complex

294 aa · 32 kDa · 4 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the…
  • ·DNA-templated transcription termination
View underlying pathways (2)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

SNRPD1GEMIN2SNRPD2DDX20STRAPSNRPESNRPGSNRPFGEMIN4GEMIN7SMN1

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 1 area

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Muscular Atrophy, Spinal1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

onasemnogene abeparvovec
Narrow target profileApprovedExogenous gene

Survival motor neuron protein exogenous gene

Indicated for Muscular Atrophy, Spinal

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SMN1

Gene-level evidence surfaced through the gene SMN1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Muscular Atrophy, Spinal
0.97Well supported

Genetic evidence dominant · Open Targets 0.73

Spinal Muscular Atrophies of Childhood
0.94Well supported

Genetic evidence dominant · Open Targets 0.81

Spinal muscular atrophy, type 1
0.88Well supported

Genetic evidence dominant · Open Targets 0.79

Proximal spinal muscular atrophy
0.86Well supported

Genetic literature evidence dominant · Open Targets 0.63

spinal muscular atrophy, type IV
0.86Well supported

Genetic evidence dominant · Open Targets 0.71

View evidence synthesis (5)
Muscular Atrophy, SpinalWell supported
0.97
agreement 0.871.00
Genetic56%Clinical41%Literature3%Genetic literaturedup

Open Targets aggregate 0.73 · 3 independent evidence families · 1 not counted as duplicate

Spinal Muscular Atrophies of ChildhoodWell supported
0.94
agreement 0.821.00
Genetic85%Animal model14%Literature2%Genetic literaturedup

Open Targets aggregate 0.81 · 3 independent evidence families · 1 not counted as duplicate

Spinal muscular atrophy, type 1Well supported
0.88
agreement 0.770.99
Genetic91%Clinical5%Literature4%Genetic literaturedup

Open Targets aggregate 0.79 · 3 independent evidence families · 1 not counted as duplicate

Proximal spinal muscular atrophyWell supported
0.86
agreement 0.760.96
Genetic literature55%Clinical25%Literature11%Animal model8%

Open Targets aggregate 0.63 · 4 independent evidence families

spinal muscular atrophy, type IVWell supported
0.86
agreement 0.740.98
Genetic82%Animal model17%Literature1%Genetic literaturedup

Open Targets aggregate 0.71 · 3 independent evidence families · 1 not counted as duplicate

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Spinal Muscular Atrophies of Childhood0.81
Spinal muscular atrophy, type 10.79
Proximal spinal muscular atrophy type 20.74
Muscular Atrophy, Spinal0.73
spinal muscular atrophy, type IV0.71
Proximal spinal muscular atrophy type 40.68
Proximal spinal muscular atrophy0.63
Neurodegenerative Diseases0.54

Drug development

1 compounds recorded · 1 approved

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (1)
ONASEMNOGENE ABEPARVOVECApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (7)
SM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Small Molecule BinderOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

1

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2026-06-30

    Approval: Itvisma (EMA)

    ema · regulatory · ema · via onasemnogene abeparvovec

  2. CHMP positive opinion2026-04-24

    CHMP positive opinion: Itvisma (EMA)

    ema · regulatory · ema · via onasemnogene abeparvovec

  3. Regulatory approval2020-05-18

    Approval: Zolgensma (EMA)

    ema · regulatory · ema · via onasemnogene abeparvovec

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.